A Study in Participants With Rheumatoid Arthritis

Inclusion Criteria:

• Diagnosis of RA of more than 6 months and less than 15 years

• At least 8 tender and swollen joints

• An abnormally high C-reactive protein (CRP) level or erythrocyte sedimentation rate (ESR)

• Positive for rheumatoid factor (RF) or anti-cyclic citrullinated peptide (CCP)antibody

• Previously treated with biologic TNF-α inhibitor therapy (infliximab, certolizumab,golimumab, etanercept, adalimumab) and stopped treatment due to insufficient efficacyor intolerance

• Regular use of at least 1 conventional disease-modifying anti-rheumatic drug (DMARD),with a stable dose for at least 8 weeks prior to study start

• Woman must not be pregnant, breastfeeding, or become pregnant during the study

Exclusion Criteria:

• Use of unstable doses of non-steroidal anti-inflammatory drugs (NSAIDS) in the past 6weeks

• Steroid injection or intravenous (IV) infusion in the last 6 weeks

• Use of more than 10 milligrams/day (mg/day) of oral steroids in the last 6 weeks

• History of a serious reaction to other biological DMARDs

• Use of an oral calcineurin inhibitor (for example, cyclosporin or tacrolimus) in thelast 8 weeks

• Surgery on a joint or other major surgery less than 2 months ago, or plans to havejoint surgery or major surgery during the study

• Active fibromyalgia, juvenile chronic arthritis, spondyloarthropathy, Crohn's disease,ulcerative colitis, psoriatic arthritis, or other systemic inflammatory conditionexcept RA

• Cervical cancer or squamous skin cancer within the past 3 years, or other cancerwithin the past 5 years

• Received a live vaccine received within the past 12 weeks (for example, vaccines formeasles, mumps, rubella, and chicken pox, and nasal-spray flu vaccines)

• Hepatitis or human immunodeficiency virus (HIV)

• A serious bacterial infection (for example, pneumonia or cellulitis) within 3 monthsor a serious bone or joint infection within 6 months

• Symptoms of herpes zoster or herpes simplex within the last month

• Active or latent tuberculosis (TB)

• Current symptoms of a serious disorder or illness

• Use of an investigational drug within the last month